Real-world Effectiveness and Cost-effectiveness of Qvar Versus FP, a US Study
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This study will compare the absolute and relative effectiveness and cost-effectiveness of
asthma management in patients in the USA on inhaled corticosteroid (ICS) maintenance therapy
as HFA-BDP (Qvar®) pressurised metered dose inhaler (pMDI) compared with fluticasone
propionate (FP) pMDI. .
Details
Lead Sponsor:
Research in Real-Life Ltd
Collaborators:
i3 Research Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries